A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies. The main aims of the study are to check the safety of ASP388B and find the most suitable dose. This study will be in 2 parts. In Part 1, different small groups of people with solid tumors will receive lower to higher doses of ASP388B. Some groups will receive ASP388B by itself, and other groups will receive ASP388B with standard cancer therapies. Any medical problems will be recorded for each dose. This is to find suitable doses of ASP388B to use in Part 2 of the study, and to include the tumor types that responded well to ASP388B. In Part 2, other different small groups of people with the specific tumor types (from Part 1) will receive the most suitable doses worked out from Part 1. Some groups will receive ASP388B by itself, and other groups will receive ASP388B with standard cancer therapies. In both parts of the study, ASP388B will be given once in 3-week cycles. The standard cancer therapies will be given according to their approved label. ASP388B and the standard cancer therapies will be given slowly through a tube into a vein. This is called an infusion. In both parts of the study, safety checks will be done at each visit, and the doctors will continue to check for medical problems throughout the study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznanie zaawansowanego guza litego, który nie może być operacyjnie usunięty lub rozprzestrzenia się na inne części ciała
- •Choroba postępowała pomimo leczenia standardowego lub pacjent nie kwalifikuje się do standardowych terapii
- •Jeden z następujących typów nowotworów: rak głowy i szyi, rak przełyku, rak prostaty (zaawansowany), rak płuca (bez drobnych komórek), drobnokomórkowy rak płuca
- •U pacjentów z rakiem prostaty: wcześniejsze leczenie innymi lekami lub chemioterapią, ze zdokumentowanym wzrostem lub rozprzestrzenianiem się choroby
- •U pacjentów z rakiem płuca: posiadanie określonych mutacji genetycznych lub wcześniejsze leczenie ukierunkowaną terapią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
START New York
Lake Success, United States
NEXT Virginia
Fairfax, United States
National Cancer Center Hospital
Chuo-ku, Japan
The Cancer Institute Hospital of JFCR
Koto-ku, Japan
Trial contact
Astellas Pharma Global Development, Inc.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.